The Congress of the European Society for Dermatology and Psychiatry (ESDaP), held in conjunction with the 2nd Brain Skin Colloquium (BSC) Conference, hosted over 60 speakers delivering 47 oral presentations, 41 poster presentations and 5 keynote talks via 2 simultaneous livestream platforms. The 2-day conference, held biennially, was due to be hosted in London, but was converted to a virtual format due to the Covid-19 pandemic. This report presents a synopsis of the conference.

Key words: psychodermatology; psycho-cutaneous medicine; quality of life; psycho-social co-morbidities.

Accepted Dec 14, 2021; Epub ahead of print Dec 14, 2021
Acta Derm Venereol 2022; 102: adv00670.
DOI: 10.2340/actadv.v101.872
Corr: Anthony Bewley, Barts Health NHS Trust; and Queen Mary University London, Royal London Hospital, London, UK. E-mail: anthony.bewley@nhs.net

The Congress of the European Society for Dermatology and Psychiatry (ESDaP), held in conjunction with the 2nd Brain Skin Colloquium (BSC) Conference, hosted over 60 speakers delivering 47 oral presentations, 41 poster presentations and 5 keynote talks via 2 simultaneous livestream platforms. The 2-day conference, held biennially, was due to be hosted in London, but was converted to a virtual format due to the Covid-19 pandemic. The conference was chaired by Professor Anthony Bewley and Dr Elise Kleyn. Professor Francoise Poot presented the outcomes of ESDaP’s newly developed psychodermatology diploma (1).

ESDaP is relatively young; it was established in 1993 in Vienna, but has now become a global psychodermatology conference. Psychodermatology clinics are becoming increasingly established globally (2), as well as clinics in resource-limited settings supported by virtual multidisciplinary teams (MDTs) (3). The BSC is even younger; the first International BSC was held in Manchester, UK, in 2017. The BSC champions clinico-academic excellence in the links between the brain and the skin.

Given that nearly 100 topics were covered during the 2-day congress, it is not possible to review all the papers and abstracts. This report presents a synopsis of the conference.

SIGNIFICANCE

Psychodermatology is an emerging and growing subspecialty of dermatology. There are few conferences in psychodermatology. The European Society for Dermatology and Psychiatry is a global organization that champions clinico-academic cutting-edge research in psychodermatology. European Society for Dermatology and Psychiatry’s conferences are biennial and are an important forum for the dissemination of psychodermatological research.

The complex relationship between stress and psoriasis indicates that biologics mediate improvements in mood, possibly via reducing brain inflammation (4), suggesting that there may be a role for anti-inflammatory interventions as a novel treatment strategy in depression (5). Like depression, there is now evidence demonstrating independent improvement in psoriasis with cognitive behavioural therapy (CBT) and mindfulness (6, 7).

The burden of chronic recalcitrant pruritus, an all too familiar clinical challenge for dermatologists, was explored by Professor Gil Yosipovitch. A notable mention went to combination formulations of topical ketamine 5–10%, lidocaine 5% and amitriptyline 5%, efficacious in all causes of chronic pruritus with a duration of up to 7 h per application. Combined therapy with sertraline and mirtazapine in patients with somatoform pruritus was also highlighted (8). As more of the pathology of this condition is unravelled, more treatments become available; interleukin-31 (IL-31) monoclonal antibodies and drugs targeting NK1 receptors (relevant to substance P).

Adding to our understanding of immunological roles in pathogenesis, new evidence points to the amygdala in amplifying the intensity of pruritus, implementing a role for muscle relaxation and CBT (9). Pruritus is now viewed as comparable to chronic pain and, thus, it becomes more logical to categorize patients based on individual’s specific immunological fingerprint. This suggests promising future new targets for highly specific tailored treatments (10).

Further understanding of the skin as a social organ is now understood to be due to C-tactile afferent fibres, which go some way to explaining the relationship between itch, pain and mind. Indeed, the role of touch through nurture, thought to be via these fibres, has lifelong effects on how one interprets and experiences
stress (11), and could even be a possible risk factor for inflammatory skin disease (12). In addition, itch is altered through learning processes, which opens the door to further novel treatment methods to alter nocebo-induced itch responses (13).

Despite the considerable progress made in pathogenesis and therapeutics, there are insufficient services to support the mental health of patients with skin disorders. Several surveys expose this gap, including the UK All-Party Parliamentary Group for Skin (APPGS), lending more weight to encouraging policy change through commissioning services (14).

We are also beginning to recognize the importance of supporting the families of patients with skin disorders as well as the patient themselves (15). The Family Dermatology Life Quality Index (DLQI) has been developed to assess this facet in order for the best support to be delivered through multidisciplinary (MDT) clinics (16). Social science has progressed considerably in the past decade, and there is evidence to show that the DLQI may need amending to reflect the subtle differences in those individuals who complete it (17), as the psychosocial burden of dermatological disorders can vary between the sexes, as well as between conditions (18). Indeed, it may be time for an updated patient-reported outcome measure (PROM) to be used in daily practice, which more accurately captures the impact on living with skin disease (19).

Whilst we are able to utilize these various tools to identify those people who will benefit from psychological interventions and support, in the UK demand still outstrips supply across the NHS. The delay in access to services often compounds the problem. Novel behaviour change training programmes, such as PsoWell™, which can be delivered by clinicians in dermatology settings, show promising potential (20).

Covid-19 has added burdens to many patients with and without skin disorders, enforcing separation, loneliness and isolation. This drives a further chasm between individuals who may already be reluctant to interact with others who have visible skin disease (21). Worryingly, many of these patients seek unregulated advice online and practice unsafe treatment regimens (22), often pursuing unrealistic, false portrayals of ideal skin showcased and practice unsafe treatment regimens (22), often pursuing unrealistic, false portrayals of ideal skin showcased on social media platforms (23). Shielding, in particular, had a dramatic effect on the wellbeing of dermatology patients (24).

The post-pandemic landscape remains unclear for patients and clinicians. Certainly, we are yet to see the full effects of the past year. Encouragingly, however, the SECURE-AD registry, which has recruited nearly 300 patients with atopic dermatitis (AD) on systematics and or dupilumab has not shown any difference in the effects, frequency or duration of long-Covid compared with non-atopics at present (25). Covid-19 has brought the subject of wellbeing amongst staff to the forefront in many departments across the NHS. Many trusts are conducting wellbeing audits to address this, and we were delighted to hear this area is becoming more of a priority (26).

Other notable presentations included the ESDaP II study, which indicated the staggeringly high prevalence of body dysmorphic disorder (BDD) symptoms in all dermatology patients compared with healthy skin controls (10.5% vs 2.1%) emphasizing the importance of screening and treating BDD in general dermatology clinics (27). BDD symptoms have also been recognized in other non-conventional disorders, including skin-lightening behaviour (28). The role of abrocitinib in facilitating a rapid and sustained improvement in pruritus, sleep and skin pain in patients with moderate-to-severe AD from as early as 2 weeks from the start of treatment was presented (29).

Other presentations included the effect of Covid-19 on patients with psychodermatological disorders (30) and the role of caregivers in identifying and solving the holistic requirements for patients with ichthyosis (31). Barlow et al. (32) reviewed suicide-related behaviours in children and adolescents with chronic skin disorders. The prevalence of suicidal attempts in children and young people was alarmingly high; ranging from 0.08% to 21.9%, inclusive of 748 children and adolescents spanning 6–17 years old. Notably, this risk does not correlate with objective severity of the skin disorder (33). Certainly, there is a role for dermatologists to be trained in this area as a means of suicide prevention (34).

A case series of 5 patients successfully treated for cutaneous immune-related adverse events with dupilumab who had previously received anti-PD1 immunotherapy was presented (35).

The experience of people with psoriasis in the context of their response to various social circumstances (36) was discussed, as were the improvements in the psychological burden of patients with eczema and neurofibromatosis I when treated remotely with eye movement desensitization and reprocessing (37).

We look forward to the 20th Congress of ESDaP, which will be held in Rotterdam, Netherlands in June 2023 and the 3rd BSC Conference in Manchester in Autumn 2024, which we hope will be face-to-face.

REFERENCES

1. Dalgard F. Characteristics of patients seen at a psychodermatology unit in Sweden. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.
2. Jafferany M. Depression and Psoriasis: How to Diagnose and manage. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.
3. Bullmore E. Inflammation and depression. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.
4. Griffiths C. Insights into the Brain-Skin Axis. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.
5. Kirby B. Psoriasis and Mindfulness. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.

6. Yosipovitch G. Mechanisms of Itch and Its Management. In: ESDAP 2021; 2021 June. Available from http://www.esdap21.com/home.

7. Misery L. Pruriplastic Itch, An Equivalent of Nociplastic Pain. In: ESDAP 2021; 2021 June. Available from http://www.esdap21.com/home.

8. McGlone F. The Skin’s Protectors: The 3 C’s. In: ESDAP 2021; 2021 June. Available from http://www.esdap21.com/home.

9. Evers A. Nocebo effects on itch as possible predictor of itch sensitization. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.

10. Thompson A. Lack of mental health support for UK skin disease patients: The 2020 All Party Parliamentary Group on Skin’s report. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.

11. Finlay A. Family impact: the hidden burden revealed by FROM-16. In: ESDAP 2021; 2021 June. Available from http://www.esdap21.com/home.

12. Bundy C. Structured Psychological Support for Dermatology Patients and Adaptations During the SARS-CoV-2 Pandemic. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.

13. Flohr C. COVID-19 in AD: lessons from the SECURE-AD physician and patient registries. In: Brain: Skin Colloquium 2021; 2021 June. Available from http://www.esdap21.com/home.

14. Cooper C. Wellbeing in the workplace. In: ESDAP 2021; 2021 June. Available from http://www.esdap21.com/home.

15. Poot F, Sampogna F, Tomas-Aragones L & Gieler U. The psychological perspective. Br J Dermatol 2021; 185: e79.

16. Ahmed A. Single-centre experience of setting up a psychodermatology clinic: making the most of what you have. Br J Dermatol 2021; 185: e83.

17. Capdevila P, Lopez-Trujillo E, Tribo MJ & Pujol RM. Psychopathological profile and response to combined therapy with mirtazapine and sertraline in patients with somatiform pruritus. Br J Dermatol 2021; 185: e74.

18. Schmidt LEM, Merdha L, Lang V, Preis S, Bleuel R, Schuch A et al. A qualitative study on maternal attachment behaviour as a risk factor for the onset of atopic dermatitis in the infant. Br J Dermatol 2021; 185: e73.

19. Day M, Heapy C, Norman P, Emerson LM, Murphy R & Thompson A. Impact of childhood psoriasis on children and parents: an interpretative phenomenological analysis. Br J Dermatol 2021; 185: e71.

20. Birjkær M, Thomsen SF, Cernica C, Bewley A & Bainton A. Using life evaluation to revise the Dermatology Life Quality Index: a multinational survey of patients with psoriasis. Br J Dermatol 2021; 185: e70.

21. Krajewski P, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G et al. Decrease in quality of life among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Br J Dermatol 2021; 185: e77.

22. Raelach P, Raelach H, Trialonis-Suthaharan N, Chachos E, Augustin M & Bundy C. Defining, understanding and measuring the impact of dermatological conditions on patients’ lives: a qualitative concept elicitation study for a new patient-reported impact of dermatological disease (PRIDD) measure. Br J Dermatol 2021; 185: e83.

23. Hewitt R, Pattinson R, Cordingley L, Griffiths C, Kley E, McAteer H et al. Implementation of the PsoWellTM model for the management of people with complex psoriasis. Br J Dermatol (in Press). Br J Dermatol 2021; 185: e72.

24. Lander K, Harris C, Al-Attar A & Kley E. Eczema and interpersonal avoidance. Br J Dermatol 2021; 185: e73.

25. Brookes T S-R, Barlow R, Mohandas P & Bewley A. Topical steroid withdrawal: an emerging clinical problem. Br J Dermatol 2021; 185: e74.

26. Tanev T. Social media and self-perception: a psychodermatological perspective. Br J Dermatol 2021; 185: e87.

27. Schut C, Dalgaard FJ, Bewley A, Evers AWM, Gieler U, Lien L et al. Prevalence of symptoms of body dysmorphic disorder in patients with dermatological conditions compared to healthy skin controls: results of the ESDAP-study-II. Br J Dermatol 2021; 185: e81.

28. Al-Sarraf A, Bewley A & Corazza O. Skin tone lightening: a psychodermatological problem? Br J Dermatol 2021; 185: e76.

29. Bewley A, Thyssen JP, Chiu WS, Rojo R, Biswas P, Feeney C et al. Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. Br J Dermatol 2021; 185: e72.

30. Shinhmár S, Lawrence L & Bewley A. The impact of the COVID-19 pandemic on psychodermatologists. Br J Dermatol 2021; 185: e90.

31. Walsh C, Leavey G & McLaughlin M. Informing the development of a Needs Assessment Tool for Ichthyosis Caregivers (NAT-IC): an international multimethod qualitative study using framework analysis. Br J Dermatol 2021; 185: e79.

32. Barlow R, Payyazghi H, Hogan S, Grindlay D, Verma M, Choi D et al. Suicide and suicidality in children and adolescents with chronic skin disorders: a systematic review. Br J Dermatol 2021; 185: e97.

33. Lada G, Talbot PS, Chinoy H, Warren RB & Kley E. Clinical correlates of depression and anxiety in psoriasis and prevalence of undiagnosed depression. Br J Dermatol 2021; 185: e71.

34. Williams P & Dimitrov D. Suicide: last resort for the prisoners trapped in ill skin. Br J Dermatol 2021; 185: e76.

35. Shatokhina E, Kruglova L & Polonskaia A. Efficacy of dupilumab in patients with immune checkpoint inhibitor-related pruritus. Br J Dermatol 2021; 185: e90.

36. Moschogianis S, Chisholm A, McKie S, Griffiths C, Elliott R & Kley E. Towards an understanding of the psychosocial impact of psoriasis. Br J Dermatol 2021; 185: e103.

37. Fellows JL, Harper N, Mortimer H & Goulding JMR. Potential utility of eye movement desensitization and reprocessing and the flash technique in psychodermatology. Br J Dermatol 2021; 185: e104.